The first publication from Symcel’s European H2020 project was published at the end of January. The project named BADGER (Bacterial Analysis and Diagnostics through Growth and Energy-release in Real-time) focuses on clinical validation for new...
The Bjarnsholt lab at the Costerton Biofilm Center finalized the purchase of a calScreener™ as part of a Novo Nordisk Fonden Tandem grant to study atopic dermatitis.
Symcel’s CEO & CSO during their visit at Professor Müller’s lab. Internationally leading group at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has acquired a calScreener to be used in their screening of novel antimicrobials. ...
Our Production and Application Engineer, Sandra Månsson, with the first calScreener she built.
Why is antibiotic resistance a global threat? The challenges of antibiotic resistance, the current situation that marks it as a WHO priority and the potential of customized therapy are some of the issues that the CEO of Symcel, Dr Jesper Ericsson,...
Our colleague Dr. Karin Gillner recently had a feature article on brown fat treatment research published in Journal for Clinical Studies.
Symcel appoints two new board members to bolster R&D business growth and expansion into the clinical diagnostics market
Internationally renowned clinical microbiologist takes academic lead in Horizon 2020 funded validation of game-changing method for multiple antibiotic resistance evaluation 11 April 2018: Symcel – the company behind the revolutionary cell-based...
L-R: Dr Marta Veses Garcia, Pelle Friberg and Dr Karin Gillner Symcel – producers of the cell-based assay tool for real-time cell metabolism measurements, calScreener — is expanding to bring its patented technology to the clinical antimicrobial...
Symcel secures €3.6 million Horizon 2020 Phase II grant for clinical validation of customized antimicrobial susceptibility testing. Multi-resistant bacterial sepsis infections to be validated utilising Symcel’s sensitive screening technology Symcel:...